A Study of the Natural Progression of Interstitial Lung Disease (ILD)

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv21
  2. Primary and study completion dates: Dec 2025 to Dec 2030
    • Collaborators: 1 to 2
    v20
  3. 2 versions Re-verified since Nov 29, 2023, no change to tracked fieldsv18-v19
  4. Primary completion date: Dec 2020 to Dec 2025v17
  5. Re-verified, no change to tracked fieldsv16
Show 14 earlier versionsHide 14 earlier versions
  1. Site contact updatedv15
  2. 2 versions Re-verified since Mar 2, 2017, no change to tracked fieldsv13-v14
  3. Eligibility criteria expanded, about 8 wordsv12
  4. Re-verified, no change to tracked fieldsv11
  5. Primary completion date: Dec 2011 to Dec 2020
    • Study completion date: Dec 2013 to Dec 2025
    v10
  6. Re-verified, no change to tracked fieldsv9
  7. Collaborator revisedv8
  8. 2 versions Re-verified since Apr 20, 2009, no change to tracked fieldsv6-v7
  9. Collaborator revisedv5
  10. Re-verified, no change to tracked fieldsv4
  11. Study completion date: Dec 2010 to Dec 2013v3
  12. Primary completion date: Dec 2011
    • Study completion date: Dec 2010
    • Start date: Sep 2005
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Trial Details
NCT Number NCT00470327
Lead Sponsor University of Chicago
Collaborators: Idiopathic Pulmonary Fibrosis Clinical Research Network, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)		 Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Related terms Connective Tissue Diseases, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Sarcoidosis
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov